Chris W Doornebal
Overview
Explore the profile of Chris W Doornebal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
1158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klarenbeek S, Doornebal C, Kas S, Bonzanni N, Bhin J, Braumuller T, et al.
Oncoimmunology
. 2020 Mar;
9(1):1724049.
PMID: 32117586
Effective treatment of invasive lobular carcinoma (ILC) of the breast is hampered by late detection, invasive growth, distant metastasis, and poor response to chemotherapy. Phosphoinositide 3-kinase (PI3K) signaling, one of...
2.
Kersten K, Coffelt S, Hoogstraat M, Verstegen N, Vrijland K, Ciampricotti M, et al.
Oncoimmunology
. 2017 Sep;
6(8):e1334744.
PMID: 28919995
Patients with primary solid malignancies frequently exhibit signs of systemic inflammation. Notably, elevated levels of neutrophils and their associated soluble mediators are regularly observed in cancer patients, and correlate with...
3.
Sekandarzad M, Van Zundert A, Doornebal C, Hollmann M
Curr Opin Anaesthesiol
. 2017 Jul;
30(5):606-612.
PMID: 28700368
Purpose Of Review: There is ongoing controversy regarding the tumor-protective effects of regional anesthesia in patients undergoing cancer surgery. Evidence of up-to-date systematic reviews will be presented alongside recent updates...
4.
Sekandarzad M, Van Zundert A, Lirk P, Doornebal C, Hollmann M
Anesth Analg
. 2016 Nov;
124(5):1697-1708.
PMID: 27828796
This narrative review discusses the most recent up-to-date findings focused on the currently available "best clinical practice" regarding perioperative anesthesia care bundle factors and their effect on tumor progression. The...
5.
Coffelt S, Kersten K, Doornebal C, Weiden J, Vrijland K, Hau C, et al.
Nature
. 2015 Mar;
522(7556):345-348.
PMID: 25822788
Metastatic disease remains the primary cause of death for patients with breast cancer. The different steps of the metastatic cascade rely on reciprocal interactions between cancer cells and their microenvironment....
6.
Doornebal C, Vrijland K, Hau C, Coffelt S, Ciampricotti M, Jonkers J, et al.
Pain
. 2015 Mar;
156(8):1424-1432.
PMID: 25734987
Morphine and other opioid analgesics are potent pain-relieving agents routinely used for pain management in patients with cancer. However, these drugs have recently been associated with a worse relapse-free survival...
7.
Doornebal C, Klarenbeek S, Braumuller T, Klijn C, Ciampricotti M, Hau C, et al.
Cancer Res
. 2012 Nov;
73(1):353-63.
PMID: 23151903
Metastatic disease accounts for more than 90% of cancer-related deaths, but the development of effective antimetastatic agents has been hampered by the paucity of clinically relevant preclinical models of human...
8.
Ciampricotti M, Hau C, Doornebal C, Jonkers J, de Visser K
Nat Med
. 2012 Mar;
18(3):344-6.
PMID: 22395693
No abstract available.
9.
Ciampricotti M, Vrijland K, Hau C, Pemovska T, Doornebal C, Speksnijder E, et al.
J Pathol
. 2011 Apr;
224(1):56-66.
PMID: 21480230
The tumour-modulating effects of the endogenous adaptive immune system are rather paradoxical. Whereas some clinical and experimental observations offer compelling evidence for the existence of immunosurveillance, other studies have revealed...